Analysts expect Trulieve to report Q3 2026 revenue of approximately $221.6 million and EPS of $0.09, with the current price of $11.22 trading well below the average analyst target of $18.18.
Investors are laser-focused on management's update regarding the Florida adult-use legalization vote and the financial impact of the recent Harvest deconsolidation. As the largest operator in Florida, the potential transition to recreational sales is the company's primary growth catalyst.
Management's ability to maintain 60% gross margins while pivoting to a medical-only model for NYSE compliance remains a critical factor for long-term valuation.